Indian pharmaceutical company Zydus Cadila on Thursday said that it has applied for the emergency use approval for its COVID-19 vaccine, ZyCoV-D. If approved, this will become the second indigenously developed vaccine after Bharat Biotech’s Covaxin, and the fifth vaccine to be approved in India, after Moderna, Covaxin, Covishield, and the Russian Sputnik V.
Zydus Cadila has conducted last-stage trials with more than 28,000 volunteers nationwide, with almost 1,000 volunteers belonging to the age group of 12 to 18.
Let’s see what makers of Zydus Cadila has claimed about the vaccine which can be administered to children:
- Zydus said, if approved, ZyCoV-D will be the world’s first DNA vaccine, as it carries a portion of the genetic code of the virus to stimulate an immune response against its spike protein.
- ZyCov-D is developed with support from the Centre’s National Biopharma Mission as part of Biotechnology Industry Research Assistance Council of department of biotechnology.
- The drug maker said the DNA vaccine showed an efficacy of 66.6% in an interim study, however no data was published on the vaccine’s effectiveness in neutralizing variants.
- The manufacturer has applied for approval of its three-dose vaccine but a two-dose regimen is also currently being evaluated.
- The three doses are managed intradermally at day 0, day 28, and finally on day 56.
- ZyCoV-D has two specific temperature requirements. For long term use it can be stored at 2 to 8 degrees Celsius, and for a short term use 25 degrees Celsius will satisfy.